What is Retatrutide?

Retatrutide is designed to combine three metabolic signals: GIP and GLP-1 receptor agonism, plus glucagon receptor agonism. That third pathway is the defining difference from tirzepatide. [3][11]

Peer-reviewed phase 2 obesity data and sponsor-announced phase 3 obesity results report large weight reductions in studied populations. Those data make retatrutide a late-stage obesity-drug candidate, not an approved medicine. [3][26][27]

Retatrutide now has phase 2 and peer-reviewed phase 3 type 2 diabetes data, plus liver-fat/MASLD-related evidence. Those results remain investigational until regulatory review and labeling are complete. [4][5][6]

What Retatrutide is investigated for

Retatrutide evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Body-weight reduction

Injectable

86% Strong

Retatrutide has moved into late-stage investigational evidence for weight management, but it remains investigational until regulatory review and labeling are complete. [26][1]

Human evidence

Phase 2 obesity data and announced phase 3 topline results show large reductions in adults with obesity or overweight. [3][26]

Animal / mechanistic evidence

Triple agonism creates a plausible stronger metabolic effect than GLP-1-only signaling, but the human phase 2 trial is the core evidence. [11]

Type 2 diabetes metabolic control

Injectable

80% Strong

The type 2 diabetes evidence now includes phase 3 data but remains investigational; it should not be read as an approved diabetes-use pathway. [4][5][1]

Human evidence

Phase 2 and peer-reviewed phase 3 type 2 diabetes trials support glycemic and weight effects, but the drug is not approved for diabetes. [4][5][1]

Animal / mechanistic evidence

GIP, GLP-1, and glucagon receptor activity all affect energy and glucose metabolism. [11]

Triple-receptor metabolic signaling

Injectable

66% Moderate

Triple-receptor signaling is the defining mechanism being studied, but clinical value still has to be judged by weight, glycemic, liver, safety, and regulatory results. [35][3]

Human evidence

Early human studies and the phase 2 program evaluate retatrutide as a triple agonist with weight, glycemic, and metabolic effects. [31][3]

Animal / mechanistic evidence

Discovery work characterizes activity across GIP, GLP-1, and glucagon receptors, which is the mechanistic reason retatrutide is separated from single- and dual-incretin drugs. [35][11]

Liver fat and MASH markers

Injectable

65% Moderate

The liver-fat signal is promising, not a settled MASH treatment claim. [6]

Human evidence

A phase 2 substudy reported liver-fat reduction in participants with MASLD. [6]

Animal / mechanistic evidence

Weight loss and glucagon-related hepatic metabolism are plausible contributors, but clinical liver benefit needs confirmatory trials. [6]

Evidence snapshot

Overall confidence

Strong

84%

Retatrutide has strong late-stage human signals for weight management, but the evidence package remains narrower than approved incretin drugs because labeling and post-approval data are not available. [3][26][27]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

84%

Human evidence

Strong

Human evidence includes phase 2 obesity and type 2 diabetes trials, a peer-reviewed phase 3 type 2 diabetes trial, a liver-fat substudy, body-composition analyses, and sponsor-announced phase 3 obesity results. [3][4][5][6][7][26]

62%

Animal / preclinical

Moderate

Discovery and pharmacology work support triple agonism, while the page confidence is driven mainly by human trial outcomes. [35][11]

80%

Mechanism support

Strong

GIP, GLP-1, and glucagon receptor activation gives a coherent rationale for appetite, body-weight, glycemic, and liver-fat effects, while also creating monitoring questions around pulse, GI tolerance, and metabolic response. [11][6]

Forms & administration

Retatrutide administration is trial-only context. Published and registered studies use protocol-controlled once-weekly subcutaneous injection; no FDA-approved public dosing, compounding, or self-directed protocol exists. [3][14][18][2][30]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common target ranges are about 1-12 mg once weekly after escalation. Phase 2 obesity arms included 1 mg, 4 mg, 8 mg, and 12 mg targets; phase 3 obesity and type 2 diabetes programs commonly evaluate 4 mg, 9 mg, and 12 mg targets. [3][14][15][18][37][26]

Frequency

Once-weekly subcutaneous injection is the published retatrutide development pattern, with protocol-defined escalation before maintenance. [3][14][18]

Timing Considerations

Weekly injection-day consistency is the main timing anchor. Published retatrutide material does not establish a meal-based, workout-based, morning, or bedtime timing advantage. [3][14][18]

Cycle Length

Retatrutide belongs to long-horizon obesity and metabolic-development programs rather than short peptide cycles. Phase 2 obesity treatment lasted about 48 weeks, TRIUMPH-1 followed participants for 80 weeks with an extension in some participants, and outcomes studies can run longer. [3][37][14][20][26][27]

Protocol Notes

Retatrutide protocol interpretation depends on dose arms, starting doses, escalation, eligibility, lab monitoring, stopping rules, rescue-medication rules, and adverse-event handling together. Isolated dose tables from unapproved seller pages or research-market vials are not equivalent to clinical-trial protocols. [14][18][30][2]

What to expect

First weeks

Appetite and fullness may shift early as dose escalation begins, while visible weight change usually builds more gradually. [3]

6-12 months

Weight and waist reductions can become more visible with sustained treatment, with larger changes more plausible after months of exposure than in the earliest weeks. [3]

Around 18 months

Continued supervised treatment can bring larger weight and waist changes, while the quality of weight loss depends on how much lean mass is preserved. [26][27][7]

After stopping

Appetite may rise again and weight maintenance may become harder once the active triple-receptor agonist signal is removed. [3][37]

Safety profile

Retatrutide safety is still investigational. Published trials support continued study, but unapproved-product exposure has produced official toxicity concerns, and glucagon-receptor activity adds monitoring questions beyond GLP-1-only drugs. [3][11][2][30]

Common side effects

Nausea [3]
Vomiting [3]
Diarrhea [3]

Cautions

Toxicity alert [30]
Import and supply risk [29]
Other incretin or weight-loss drugs [3][11]

What we don't know

Rare events, long-term safety, discontinuation effects, and special-population safety remain unsettled while phase 3 and post-approval-style evidence are still developing. [26][16]

Who Retatrutide is not for

Route-specific avoid and medical-review notes:

Pregnancy and special populations
Until labeling exists, pregnancy, breastfeeding, pediatric use, frailty, significant endocrine disease, and complex metabolic disease should be treated as trial-exclusion-level concerns. [12][1]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Other incretin or weight-loss drugs
Combining retatrutide with GLP-1, GIP, amylin, or other weight-loss drugs could amplify GI, pulse, glucose, and dehydration risks; combination evidence is not established. [3][11]

Pairing notes

Not recommended with

Stacking with GLP-1 or GIP drugs Injectable

Retatrutide is already a multi-receptor agonist; combining it with semaglutide, tirzepatide, or other satiety drugs lacks established safety and efficacy evidence. [11]

Regulatory status

United States

United States: not FDA-approved for human use as a drug; FDA also states retatrutide cannot be used in compounding under federal law. [1][2]

Route	FDA drug approval	503A compounding
Injectable	Not Approved Retatrutide is not FDA-approved for human use as a drug in the United States. [1][2]	Not Listed FDA states retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. [2]

Injectable

FDA drug approval

Not Approved

Retatrutide is not FDA-approved for human use as a drug in the United States. [1][2]

503A compounding

Not Listed

FDA states retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. [2]

International

International status is country-specific; official Australian guidance and a Victoria Health alert highlight risks around unapproved peptide products. [29][30]

Sports & competition

For athletes, retatrutide may fall under WADA non-approved-substance rules because it is not approved by a governmental regulatory health authority for human therapeutic use. [1][28]

How it works

Retatrutide is a triple agonist: it activates GLP-1, GIP, and glucagon receptors, making it different from single GLP-1 agonists and dual GIP/GLP-1 drugs. [3][11]

GLP-1 and GIP explain the satiety and glycemic side; glucagon receptor activity adds energy-expenditure and liver-metabolism biology, but also makes pulse, glucose, and tolerability interpretation more important. Receptor names alone are not enough. [11][3][6]

Human data make the program interesting, but retatrutide remains investigational; the mechanism does not establish approval, retail dosing rules, or safe stacking with other weight-loss drugs, especially from informal supply. [3][1][30]

Research gaps & open questions

What the current literature has not yet settled about Retatrutide:

Full peer-reviewed phase 3 obesity publications and regulatory review are now central evidence gaps. The phase 3 type 2 diabetes publication improves the evidence base but does not establish approval, labeling, or long-term safety. [26][5][1]

Long-term glucagon-receptor activation needs careful safety interpretation around heart rate, glycemia, liver outcomes, gallbladder events, lean mass, and special populations. [11][6]

Consumer-market safety cannot be inferred from clinical trials. Official toxicity alerts make product identity, purity, and dosing accuracy a separate risk area. [30][29]

Common questions

Is retatrutide FDA-approved?

No. Retatrutide is not FDA-approved for human use as a drug, and FDA states it cannot be used in compounding under federal law. [1][2]

What does triple agonist mean?

It means retatrutide activates three hormone receptors: GIP, GLP-1, and glucagon. That is the main pharmacology difference from tirzepatide. [11]

Is retatrutide just stronger tirzepatide?

Not exactly. Both include GIP and GLP-1 receptor activity, but retatrutide adds glucagon receptor agonism and remains investigational. [11]

Myths & misconceptions

Myth

Large retatrutide trial weight loss means it is ready for normal use.

Reality

Large trial results are promising but do not replace approval review, labeled manufacturing, and real-world safety monitoring. [26][1]

Myth

Research-market retatrutide is the same as trial retatrutide.

Reality

Clinical-trial material is controlled and monitored. Official health alerts about unapproved retatrutide products make that distinction important. [30][29]

History & discovery

Retatrutide entered the obesity pipeline as LY3437943, a triple GIP, GLP-1, and glucagon receptor agonist. Its history is still an investigational-drug story, not an approved-product story, and that distinction should stay visible. [35][31][3][1]

Early LY3437943 and phase 2 obesity/type 2 diabetes publications made retatrutide visible as a triple-agonist candidate with human body-weight and metabolic signals. [35][31][3][4]

MASLD data and TRIUMPH materials broadened the program, while unapproved-product alerts reinforced the gap between monitored trials and informal retatrutide supply, consumer availability, and safety assumptions. [6][37][26][30]

Published research 51 studies

[1]

openFDA Drugs@FDA query for retatrutide

openFDA / U.S. Food and Drug Administration. database query.

[2]

FDA's concerns with unapproved GLP-1 drugs used for weight loss

U.S. Food and Drug Administration. regulatory.

[3]

Triple-Hormone-Receptor Agonist Retatrutide for Obesity

New England Journal of Medicine. human clinical.

[4]

Retatrutide for type 2 diabetes: a randomised, double-blind, placebo and active-controlled phase 2 trial

The Lancet. human clinical.

[5]

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Lancet (London, England), 2026. human clinical.

[6]

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease

Nature Medicine. human clinical.

[7]

Effects of retatrutide on body composition in people with type 2 diabetes and/or obesity: a post-hoc analysis

The Lancet. Diabetes & endocrinology. human clinical.

[8]

Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes

The Journal of clinical endocrinology and metabolism, 2026. human clinical.

[9]

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity

Kidney international reports, 2025. human clinical.

[10]

Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease

Nephrology, dialysis, transplantation, 2026. human clinical.

[11]